LY 3200882 Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 470

Clinical Trials

LY 3200882 has been evaluated across several clinical trials, encompassing Phase 1 and Phase 1/2 studies for solid tumors, metastatic colorectal cancer, advanced cancer, and pharmacokinetic evaluations in healthy volunteers. The clinical program involves major industry sponsors, including Eli Lilly and Company and Merck Sharp & Dohme LLC, alongside academic networks such as The Netherlands Cancer Institute and the EORTC. Recruitment statuses across these investigations vary, encompassing completed studies, active non-recruiting trials, and withdrawn protocols.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04158700	WITHDRAWN	Advanced Cancer	Eli Lilly and Company	2019-12-05	PHASE1; PHASE2
NCT02937272	ACTIVE_NOT_RECRUITING	Solid Tumor	Eli Lilly and Company	2016-11-21	PHASE1
NCT04031872	Unknown status	Colorectal Cancer Metastatic	The Netherlands Cancer Institute\|Vall d''Hebron Institute of Oncology\|Agendia\|European Organisation for Research and Treatment of Cancer - EORTC\|Azienda Ospedaliera Niguarda Cà Granda\|Fundación para la Investigación del Hospital Clínico de Valencia\|University of Campania Luigi Vanvitelli\|University of Turin Italy\|Eli Lilly and Company\|Catalan Institute of Health\|Universitaire Ziekenhuizen KU Leuven	2020-02	Phase 1\|Phase 2
NCT04031872	WITHDRAWN	Colorectal Cancer Metastatic	The Netherlands Cancer Institute	2020-01-01	PHASE1; PHASE2
NCT04158700	Withdrawn	Advanced Cancer	Eli Lilly and Company\|Merck Sharp & Dohme LLC	2019-12-05	Phase 1\|Phase 2
NCT03792139	COMPLETED	Healthy	Eli Lilly and Company	2019-01-08	PHASE1
NCT03792139	Completed	Healthy	Eli Lilly and Company	2019-01-08	Phase 1

(data from https://clinicaltrials.gov, updated on 2020-02-19)

Check the LY 3200882 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

LY 3200882 functions as a potent and selective inhibitor of TGF-β receptor type 1 (TGFβRI), binding the receptor to block downstream TGF-β-mediated SMAD phosphorylation. This disruption suppresses immunosuppressive signaling in tumor and immune cells, inhibiting tumor growth in clinical contexts such as advanced solid tumors and metastatic colorectal cancer.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).